A groundbreaking study published in the New England Journal of Medicine has revealed compelling evidence that administering medications for opioid use disorder (MOUD) within county jails significantly improves post-release outcomes, including treatment retention, reduction in overdose fatalities, and lower reincarceration rates. This research, funded by the National Institute on Drug Abuse and conducted across seven Massachusetts county jails, addresses a critical gap in addiction treatment among incarcerated populations—underscoring jails as pivotal intervention points in the ongoing opioid crisis.
The opioid epidemic continues to ravage communities across the United States, with over 80,000 opioid-related deaths reported in 2024 alone. Individuals with opioid use disorder (OUD) are disproportionately represented in correctional settings, yet only a fraction of jails nationwide offer MOUD. This study highlights the life-saving potential of integrating FDA-approved medications—buprenorphine, methadone, and naltrexone—into jail-based treatment programs, challenging systemic barriers that limit access during incarceration.
Through an extensive analysis of data from 6,400 incarcerated individuals with probable OUD between September 2019 and December 2020, researchers observed that 42% received MOUD while detained. These individuals were markedly more likely to sustain treatment adherence post-release compared to those who did not receive MOUD, with continuation rates at six months post-release reaching nearly 58%. In stark contrast, only 23% of untreated individuals remained engaged in opioid disorder treatment programs, underscoring the efficacy of jail-initiated MOUD.
Importantly, the study documented a striking 52% reduction in fatal opioid overdoses among individuals treated with MOUD while incarcerated. Non-fatal overdoses decreased by 24%, total mortality by 56%, and reincarceration risks dropped by 12% relative to their untreated counterparts. These multifaceted benefits substantiate MOUD as not only a harm reduction tool but a critical strategy that extends beyond clinical treatment to encompass broader social and criminal justice outcomes.
Massachusetts stands at the forefront of this transformative approach due to legislation enacted in 2018 mandating a four-year pilot program to provide comprehensive MOUD in select county jails. This legislation necessitates the continuation of pre-incarceration MOUD treatment, initiation of treatment prior to release, and seamless linkages to community care—addressing discontinuity in care that has historically exacerbated relapse and overdose risk post-release. This structured initiative provided a unique environment to rigorously evaluate the impact of jail-based MOUD programs on a large scale.
Methodologically, the research leveraged cross-sector data integration, combining self-reported information from incarcerated individuals with detailed clinical records, jail administrative data, and public health datasets through the Massachusetts Public Health Data Warehouse. This linkage spans over 35 state databases, allowing for robust monitoring of treatment trajectories, overdose events, mortality, and reincarceration, thereby offering unprecedented insight into longitudinal outcomes associated with jail-based MOUD programs.
Treatment engagement during incarceration proved to be a strong predictor of sustained community treatment adherence. Notably, more than 60% of those who received MOUD in jail initiated community-based treatment within 30 days of release, a rate over threefold higher than those untreated during incarceration. Furthermore, sustained medication adherence was observed in 50% of treated individuals for at least 75% of the first 90 days post-release, illustrating the critical role of jail-based treatment in establishing long-term recovery trajectories.
Buprenorphine was the predominant medication administered, accounting for nearly 68% of MOUD treatments in jail, followed by methadone and naltrexone. This distribution reflects evolving clinical preferences and accessibility, with buprenorphine’s safety profile and ease of administration likely contributing to its widespread use. Future research is needed to delineate differential outcomes by medication type and to optimize individualized treatment protocols within correctional environments.
The authors emphasize the broader implications of their findings, positing jail-based MOUD programs as a model for public health interventions that confront the opioid crisis at one of its most vulnerable junctures. By bridging gaps in treatment continuity, jails evolve from mere holding facilities to critical nodes in national efforts aimed at promoting recovery, reducing mortality, and curtailing cycles of relapse and recidivism that strain communities and criminal justice systems alike.
Despite these advances, MOUD implementation in jails nationwide remains limited, available in only approximately 13% of facilities and frequently restricted to narrowly defined populations such as pregnant women. The study advocates for widespread policy reform to increase MOUD accessibility across jails, thereby reducing systemic inequities and addressing the public health imperative to treat OUD comprehensively within correctional institutions.
This research was conducted in collaboration with the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN) and the Massachusetts Department of Public Health, representing a multifaceted partnership that bridges clinical, public health, and correctional systems. The integration of these diverse perspectives ensures that findings have practical relevance for policymakers, practitioners, and community stakeholders committed to tackling addiction within justice-involved populations.
Looking forward, the study calls for further investigations into generalizability across diverse correctional systems and populations, examining how variables such as demographic factors, local resources, and specific medications influence outcomes. Additionally, research exploring implementation science strategies to streamline MOUD delivery, enhance patient engagement, and support ongoing recovery post-release remains essential to maximize the public health impact of these programs.
In sum, providing MOUD in county jails emerges as a potent intervention to improve health outcomes, reduce mortality, and disrupt cycles of incarceration associated with opioid use disorder. As the opioid epidemic continues to evolve, this evidence-based approach offers a powerful blueprint for transforming criminal justice settings into pivotal arenas for addiction treatment and recovery.
Subject of Research: Medications for opioid use disorder in correctional settings and their impact on post-release outcomes.
Article Title: Medications for Opioid Use Disorder in County Jails: Outcomes After Release.
News Publication Date: September 11, 2025
Web References:
- New England Journal of Medicine Article: http://dx.doi.org/10.1056/NEJMsa2415987
- Massachusetts Public Health Data Warehouse: https://www.mass.gov/public-health-data-warehouse-phd
- National Institute on Drug Abuse (NIDA): https://www.nida.nih.gov
References:
PD Friedmann, et al. Medications for Opioid Use Disorder in County Jails: Outcomes After Release. New England Journal of Medicine. DOI: 10.1056/NEJMsa2415987 (2025).
Keywords: Opioid addiction, Medications for opioid use disorder, Jail-based treatment, Overdose prevention, Incarceration, Substance use disorders, Public health interventions, Reincarceration reduction, Buprenorphine, Methadone, Naltrexone, Criminal justice system.
